Rebekah...As you say, when and if we receive regulatory approvals for ATH434 for MSA from the FDA and other worldwide agencies, I think there will be speedy and significant off-label usage by Parkinson's patients at the recommendation of their neurologists. That would be nice, lucrative, and hopefully bode well for our future clinical trials for Parkinson's too.
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-166
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $184.6K | 61.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 75735096 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 33814069 | 6 |
View Market Depth
| Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |